Kymera Therapeutics, Inc.

NASDAQ:KYMR

40.11 (USD) • At close December 27, 2024
Bedrijfsnaam Kymera Therapeutics, Inc.
Symbool KYMR
Munteenheid USD
Prijs 40.11
Beurswaarde 2,597,736,183
Dividendpercentage 0%
52-weken bereik 22.35 - 53.27
Industrie Biotechnology
Sector Healthcare
CEO Dr. Nello Mainolfi M.D., Ph.D.
Website https://www.kymeratx.com

An error occurred while fetching data.

Over Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis

Vergelijkbare Aandelen

TransMedics Group, Inc. logo

TransMedics Group, Inc.

TMDX

61.02 USD

NanoString Technologies, Inc. logo

NanoString Technologies, Inc.

NSTG

0.105 USD

Organogenesis Holdings Inc. logo

Organogenesis Holdings Inc.

ORGO

3.19 USD

Health Catalyst, Inc. logo

Health Catalyst, Inc.

HCAT

7.08 USD

AngioDynamics, Inc. logo

AngioDynamics, Inc.

ANGO

8.91 USD

Alphatec Holdings, Inc. logo

Alphatec Holdings, Inc.

ATEC

9.19 USD

Alector, Inc. logo

Alector, Inc.

ALEC

1.78 USD

Cue Health Inc. logo

Cue Health Inc.

HLTH

0.043 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)